At the news
? BULLISHIMPACT 7/10 8-K filed Apr 7, 2026 at 06:33 ET
Nuvalent, Inc. announced the submission of its New Drug Application (NDA) to the U.S. FDA for neladalkib, a treatment for tyrosine kinase inhibitor pre-treated advanced ALK-positive non-small cell lung cancer. This is a key regulatory milestone in the company's oncology pipeline.
- Nuvalent submitted a New Drug Application (NDA) to the FDA for neladalkib.
- The drug candidate targets advanced ALK-positive non-small cell lung cancer in patients previously treated with tyrosine kinase inhibitors.
- The announcement represents a significant advancement in the company's clinical development program.
- No financial figures or timelines for FDA decision were disclosed in the filing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access